8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Randhawa A, Ganguly K, Dutta SD, Patil TV, Lim K-T

Bioeffects Seen

Authors not listed · 2025

Share:

This COVID-19 drug study was incorrectly classified as EMF research, highlighting database accuracy issues.

Plain English Summary

Summary written for general audiences

This study appears to be misclassified in the EMF Research Hub database - it actually examined COVID-19 antiviral treatments (molnupiravir and nirmatrelvir-ritonavir) in hospitalized patients, not electromagnetic field exposure. The RECOVERY trial found that adding these oral antivirals to usual care did not improve clinical outcomes like mortality or hospital stay duration in 923 and 137 patients respectively.

Why This Matters

This study represents a database classification error - it's a pharmaceutical trial studying COVID-19 antivirals, not EMF research. This highlights an important issue in EMF health research: the need for rigorous categorization and quality control in research databases. When legitimate EMF studies get mixed with unrelated medical research, it can undermine the credibility of the field and make it harder for people to find the real science on electromagnetic field health effects.

What this means for you: Always verify that EMF studies actually examine electromagnetic field exposure. Real EMF research should specify frequency ranges, power levels, exposure duration, and biological endpoints related to electromagnetic fields. The confusion between different types of health research can muddy the waters when you're trying to understand genuine EMF health risks from sources like cell phones, WiFi, and power lines.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2025). Randhawa A, Ganguly K, Dutta SD, Patil TV, Lim K-T.
Show BibTeX
@article{randhawa_a_ganguly_k_dutta_sd_patil_tv_lim_k_t_ce4187,
  author = {Unknown},
  title = {Randhawa A, Ganguly K, Dutta SD, Patil TV, Lim K-T},
  year = {2025},
  doi = {10.1016/s1473-3099(25)00093-3},
  
}
DOI: 10.1016/s1473-3099(25)00093-3PubMed: 40383127

Quick Questions About This Study

This appears to be a database classification error. The study examined oral COVID-19 medications, not electromagnetic field exposure, and should not be included in EMF health research collections.
The RECOVERY trial tested whether adding molnupiravir or nirmatrelvir-ritonavir antiviral drugs to usual care improved outcomes in hospitalized COVID-19 patients. It found no significant clinical benefits.
The molnupiravir comparison included 923 participants (445 treatment, 478 control), while the nirmatrelvir-ritonavir comparison included 137 participants (68 treatment, 69 control) across multiple hospitals.
Both antiviral treatments showed identical 17-19% mortality rates compared to usual care alone, with no statistically significant differences in 28-day survival outcomes between treatment and control groups.
Both antiviral comparisons were stopped due to low patient recruitment, which limited the study's ability to detect clinically meaningful treatment benefits, particularly for the smaller nirmatrelvir-ritonavir group.